Multimodality Treatment for Invasive Pituitary Adenomas

References

• . Ezzat S, Asa SL, Couldwell WT,. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;101(3):613–619
   PubMed Web of Science ®Google Scholar
• . Beauregard C, Truong U, Hardy J, Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol (Oxf). 2003;58(1):86–91
   PubMed Web of Science ®Google Scholar
• . Grisoli F, Leclercq T, Jaquet P,. Transsphenoidal surgery for acromegaly–long-term results in 100 patients. Surg Neurol. 1985;23(5):513–519
   PubMedGoogle Scholar
• . Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure.’ Eur J Endocrinol. 2005;152(3):379–387
   PubMed Web of Science ®Google Scholar
• . Hashimoto N, Handa H, Yamashita J, Yamagami T. Long-term follow-up of large or invasive pituitary adenomas. Surg Neurol. 1986;25(1):49–54
   PubMedGoogle Scholar
• . Martins AN, Hayes GJ, Kempe LG. Invasive pituitary adenomas. J Neurosurg. 1965;22:268–276
   PubMed Web of Science ®Google Scholar
• . Ezzat S, Snyder PJ, Young WF,. Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med. 1992;117(9):711–718
   PubMed Web of Science ®Google Scholar
• . Hofmann BM, Fahlbusch R. Treatment of Cushing's disease: a retrospective clinical study of the latest 100 cases. Front Horm Res. 2006;34:158–184
   PubMed Web of Science ®Google Scholar
• . Losa M, Valle M, Mortini P,. Gamma knife surgery for treatment of residual nonfunctioning pituitary adenomas after surgical debulking. J Neurosurg. 2004;100(3):438–444
   PubMed Web of Science ®Google Scholar
• . Kokubo M, Sasai K, Shibamoto Y,. Long-term results of radiation therapy for pituitary adenoma. J Neurooncol. 2000;47(1):79–84
   PubMed Web of Science ®Google Scholar
• . Meij BP, Lopes MB, Ellegala DB, Alden TD, Laws ER Jr. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg. 2002;96(2):195–208
   PubMed Web of Science ®Google Scholar
• . Selman WR, Laws ER Jr, Scheithauer BW, Carpenter SM. The occurrence of dural invasion in pituitary adenomas. J Neurosurg. 1986;64(3):402–407
   PubMed Web of Science ®Google Scholar
• . Burger PC, Scheithauer BW, Vogel FS. The region of the sella turcica. Surgical Pathology of the Nervous System and its Coverings. 4th ed. Philadelphia, PA: Churchill Livingstone; 2002:437–498
   Google Scholar
• . Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB. Clinical review: Diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab. 2005;90(5):3089–3099
   PubMed Web of Science ®Google Scholar
• . Kontogeorgos G. Classification and pathology of pituitary tumors. Endocrine. 2005;28(1):27–35
   PubMedGoogle Scholar
• . Tanaka Y, Hongo K, Tada T, Sakai K, Kakizawa Y, Kobayashi S. Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patient age, and MIB-1 index. J Neurosurg. 2003;98(2):359–365
   PubMed Web of Science ®Google Scholar
• . Thapar K, Kovacs K, Scheithauer BW,. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery. 1996;38(1):99–106; discussion 106–107
   PubMed Web of Science ®Google Scholar
• . Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery. 1996;38(4):765–770; discussion 770–771
   PubMed Web of Science ®Google Scholar
• . Kovacs K, Scheithauer BW, Horvath E, Lloyd RV. The World Health Organization classification of adenohypophysial neoplasms. A proposed five-tier scheme. Cancer. 1996;78(3):502–510
   PubMed Web of Science ®Google Scholar
• . Oldfield EH, Vortmeyer AO. Development of a histological pseudocapsule and its use as a surgical capsule in the excision of pituitary tumors. J Neurosurg. 2006;104(1):7–19
   PubMed Web of Science ®Google Scholar
• . Scheithauer BW, Kovacs KT, Laws ER Jr, Randall RV. Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg. Dec 1986;65(6):733–744
   PubMed Web of Science ®Google Scholar
• . Ragel BT, Couldwell WT. Pituitary carcinoma: a review of the literature. Neurosurg Focus. 2004;16(4):E7
   PubMedGoogle Scholar
• . Scotti G, Yu CY, Dillon WP,. MR imaging of cavernous sinus involvement by pituitary adenomas. AJR Am J Roentgenol. 1988;151(4):799–806
   PubMed Web of Science ®Google Scholar
• . Pinker K, Ba-Ssalamah A, Wolfsberger S, Mlynarik V, Knosp E, Trattnig S. The value of high-field MRI (3T) in the assessment of sellar lesions. Eur J Radiol. 2005;54(3):327–334
   PubMed Web of Science ®Google Scholar
• . Kucharczyk W, Bishop JE, Plewes DB, Keller MA, George S. Detection of pituitary microadenomas: comparison of dynamic keyhole fast spin-echo, unenhanced, and conventional contrast-enhanced MR imaging. AJR Am J Roentgenol. 1994;163(3):671–679
   PubMed Web of Science ®Google Scholar
• . Vieira JO Jr, Cukiert A, Liberman B. Evaluation of magnetic resonance imaging criteria for cavernous sinus invasion in patients with pituitary adenomas: logistic regression analysis and correlation with surgical findings. Surg Neurol. 2006;65(2):130–135; discussion 135
   PubMedGoogle Scholar
• . Cottier JP, Destrieux C, Brunereau L,. Cavernous sinus invasion by pituitary adenoma: MR imaging. Radiology. 2000;215(2):463–469
   PubMed Web of Science ®Google Scholar
• . Luo CB, Teng MM, Chen SS,. Imaging of invasiveness of pituitary adenomas. Kaohsiung J Med Sci. 2000;16(1):26–31
   PubMedGoogle Scholar
• . Vance ML. Perioperative management of patients undergoing pituitary surgery. Endocrinol Metab Clin North Am. 2003;32(2):355–365
   PubMed Web of Science ®Google Scholar
• . Molitch ME. Pharmacologic resistance in prolactinoma patients. Pituitary. 2005;8(1):43–52
   PubMedGoogle Scholar
• . Couldwell WT. Transsphenoidal and transcranial surgery for pituitary adenomas. J Neurooncol. 2004;69(1–3):237–256
   PubMed Web of Science ®Google Scholar
• . Couldwell WT, Weiss MH. The transnasal trassphenoidal approach. In: Apuzzo ML, ed. Surgery of the Third Ventricle. 2nd ed. Baltimore, MD: Williams and Wilkins; 1998;553–574
   Google Scholar
• . Patterson RH. The role of transcranial surgery in the management of pituitary adenoma. Acta Neurochir Suppl. 1996;65:16–17
   PubMedGoogle Scholar
• . Youssef AS, Agazzi S, van Loveren HR. Transcranial surgery for pituitary adenomas. Neurosurgery. 2005;57( 1 suppl):168–175; discussion 168–175
   PubMed Web of Science ®Google Scholar
• . Gnanalingham KK, Bhattacharjee S, Pennington R, Ng J, Mendoza N. The time course of visual field recovery following transphenoidal surgery for pituitary adenomas: predictive factors for a good outcome. J Neurol Neurosurg Psychiatry. 2005;76(3):415–419
   PubMed Web of Science ®Google Scholar
• . Colao A, Attanasio R, Pivonello R,. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2006;91(1):85–92
   PubMed Web of Science ®Google Scholar
• . Yu C, Wu Z, Gong J. Combined treatment of invasive giant prolactinomas. Pituitary. 2005;8(1):61–65
   PubMedGoogle Scholar
• . Couldwell WT, Rosenow JM, Rovit RL, Benzil DL. Hypophysopexy technique for radiosurgical treatment of cavernous sinus pituitary adenoma. Pituitary. 2002;5(3):169–173
   PubMedGoogle Scholar
• . Meyer A, Behrend M. Cushing's syndrome: adrenalectomy and long-term results. Dig Surg. 2004;21(5–6):363–370
   PubMed Web of Science ®Google Scholar
• . Nelson DH, Meakin JW, Dealy JB Jr, Matson DD, Emerson K Jr, Thorn GW. ACTH-producing tumor of the pituitary gland. N Engl J Med. 1958;259(4):161–164
   PubMed Web of Science ®Google Scholar
• . Assie G, Bahurel H, Bertherat J, Kujas M, Legmann P, Bertagna X. The Nelson's syndrome… revisited. Pituitary. 2004;7(4):209–215
   PubMedGoogle Scholar
• . Jenkins PJ, Trainer PJ, Plowman PN,. The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab. 1995;80(1):165–171
   PubMed Web of Science ®Google Scholar
• . Couldwell WT, Weiss MH, Laws ER Jr. Prolactinomas. N Engl J Med. 2004;350(10):1054–1057; author reply 1054–1057
   PubMedGoogle Scholar
• . Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev. 1992;13(2):220–240
   PubMed Web of Science ®Google Scholar
• . Freda PU, Reyes CM, Nuruzzaman AT, Sundeen RE, Khandji AG, Post KD. Cabergoline therapy of growth hormone and growth hormone/prolactin secreting pituitary tumors. Pituitary. 2004;7(1):21–30
   PubMedGoogle Scholar
• . Cozzi R, Attanasio R, Barausse M,. Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur J Endocrinol. 1998;139(5):516–521
   PubMed Web of Science ®Google Scholar
• . Colao A, Ferone D, Marzullo P,. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab. 1997;82(2):518–523
   PubMed Web of Science ®Google Scholar
• . Greenman Y, Tordjman K, Osher E,. Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth. Clin Endocrinol (Oxf). 2005;63(1):39–44
   PubMed Web of Science ®Google Scholar
• . Giusti M, Bocca L, Florio T,. Cabergoline modulation of alpha-subunits and FSH secretion in a gonadotroph adenoma. J Endocrinol Invest. 2000;23(7):463–466
   PubMed Web of Science ®Google Scholar
• . Pawlikowski M, Pisarek H, Kunert-Radek J, Radek A. Immunohistochemical detection of somatostatin receptor subtypes in “clinically nonfunctioning” pituitary adenomas. Endocr Pathol. 2003;14(3):231–238
   PubMed Web of Science ®Google Scholar
• . Jaquet P, Gunz G, Saveanu A,. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest. 2005;28( 11 suppl international):21–27
   PubMedGoogle Scholar
• . Jaquet P, Saveanu A, Barlier A. New SRIF analogs in the control of human pituitary adenomas: perspectives. J Endocrinol Invest. 2005;28( 5 suppl):14–18
   PubMedGoogle Scholar
• . Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2002;87(7):3013–3018
   PubMed Web of Science ®Google Scholar
• . Mannavola D, Persani L, Vannucchi G,. Different responses to chronic somatostatin analogues in patients with central hyperthyroidism. Clin Endocrinol (Oxf). 2005;62(2):176–181
   PubMed Web of Science ®Google Scholar
• . Petersenn S. Efficacy and limits of somatostatin analogs. J Endocrinol Invest. 2005;28( 11 suppl):53–57
   PubMedGoogle Scholar
• . Paisley AN, Trainer P, Drake W. Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly. Expert Opin Biol Ther. 2004;4(3):421–425
   PubMed Web of Science ®Google Scholar
• . Dimaraki EV, Symons KV, Barkan AL. Raloxifene decreases serum IGF-I in male patients with active acromegaly. Eur J Endocrinol. 2004;150(4):481–487
   PubMed Web of Science ®Google Scholar
• . Gruszka A, Kunert-Radek J, Pawlikowski M. Rosiglitazone, PPARgamma receptor ligand, decreases the viability of rat prolactin-secreting pituitary tumor cells in vitro. Neuro Endocrinol Lett. 2005;26(1):51–54
   PubMed Web of Science ®Google Scholar
• . Bogazzi F, Ultimieri F, Raggi F,. PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas. Eur J Endocrinol. 2004;150(6):863–875
   PubMed Web of Science ®Google Scholar
• . Vance ML. Medical treatment of functional pituitary tumors. Neurosurg Clin N Am. 2003;14(1):81–87
   PubMed Web of Science ®Google Scholar
• . Fadul CE, Kominsky AL, Meyer LP,. Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg. 2006;105(4):621–626
   PubMed Web of Science ®Google Scholar
• . Kaltsas GA, Mukherjee JJ, Plowman PN, Monson JP, Grossman AB, Besser GM. The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J Clin Endocrinol Metab. 1998;83(12):4233–1238
   PubMed Web of Science ®Google Scholar
• . McIntyre DJ, Robinson SP, Howe FA,. Single dose of the anti-vascular agent, ZD6126 (N-acetylcolchinol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor model. Neoplasia. 2004;6(2):150–157
   PubMed Web of Science ®Google Scholar
• . van den Bergh AC, van den Berg G, Schoorl MA,. Immediate postoperative radiotherapy in residual nonfunctioning pituitary adenoma: beneficial effect on local control without additional negative impact on pituitary function and life expectancy. Int J Radiat Oncol Biol Phys. 2007;67(3):863–869
   PubMed Web of Science ®Google Scholar
• . Park P, Chandler WF, Barkan AL,. The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. Neurosurgery. 2004;55(1):100–106; discussion 106–107
   PubMed Web of Science ®Google Scholar
• . Zierhut D, Flentje M, Adolph J, Erdmann J, Raue F, Wannenmacher M. External radiotherapy of pituitary adenomas. Int J Radiat Oncol Biol Phys. 1995;33(2):307–314
   PubMed Web of Science ®Google Scholar
• . Estrada J, Boronat M, Mielgo M,. The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med. 1997;336(3):172–177
   PubMed Web of Science ®Google Scholar
• . Tsang RW, Brierley JD, Panzarella T, Gospodarowicz MK, Sutcliffe SB, Simpson WJ. Role of radiation therapy in clinical hormonally-active pituitary adenomas. Radiother Oncol. 1996;41(1):45–53
   PubMed Web of Science ®Google Scholar
• . Movsas B, Movsas TZ, Steinberg SM, Okunieff P. Long-term visual changes following pituitary irradiation. Int J Radiat Oncol Biol Phys. 1995;33(3):599–605
   PubMed Web of Science ®Google Scholar
• . Bhansali A, Banerjee AK, Chanda A,. Radiation-induced brain disorders in patients with pituitary tumours. Australas Radiol. 2004;48(3):339–346
   PubMedGoogle Scholar
• . Hill MD, Mackenzie I, Mason WP. Radiation-induced glioma presenting as diffuse leptomeningeal gliomatosis: a case report. J Neurooncol. 2001;55(2):113–116
   PubMed Web of Science ®Google Scholar
• . Snyder PJ, Fowble BF, Schatz NJ, Savino PJ, Gennarelli TA. Hypopituitarism following radiation therapy of pituitary adenomas. Am J Med. 1986;81(3):457–162
   PubMed Web of Science ®Google Scholar
• . Barnett GH, Linskey ME, Adler JR,. Stereotactic radiosurgery–an organized neurosurgery-sanctioned definition. J Neurosurg. 2006;106(1):1–5
   Web of Science ®Google Scholar
• . Ajithkumar T, Brada M. Stereotactic linear accelerator radiotherapy for pituitary tumors. Treat Endocrinol. 2004;3(4):211–216
   PubMedGoogle Scholar
• . Baumert BG, Norton IA, Lomax AJ, Davis JB. Dose conformation of intensity-modulated stereotactic photon beams, proton beams, and intensity-modulated proton beams for intracranial lesions. Int J Radiat Oncol Biol Phys. 2004;60(4):1314–1324
   PubMed Web of Science ®Google Scholar
• . Pollock BE, Carpenter PC. Stereotactic radiosurgery as an alternative to fractionated radiotherapy for patients with recurrent or residual nonfunctioning pituitary adenomas. Neurosurgery. 2003;53(5):1086–1091; discussion 1091–1094
   PubMed Web of Science ®Google Scholar
• . Sheehan JP, Kondziolka D, Flickinger J, Lunsford LD. Radiosurgery for residual or recurrent nonfunctioning pituitary adenoma. J Neurosurg. 2002;97( 5 suppl):408–414
   PubMed Web of Science ®Google Scholar
• . Jane JA Jr, Vance ML, Woodburn CJ, Laws ER Jr. Stereotactic radiosurgery for hypersecreting pituitary tumors: part of a multimodality approach. Neurosurg Focus. 2003;14(5):E12
   PubMedGoogle Scholar
• . Pollock BE, Nippoldt TB, Stafford SL, Foote RL, Abboud CF. Results of stereotactic radiosurgery in patients with hormone-producing pituitary adenomas: factors associated with endocrine normalization. J Neurosurg. 2002;97(3):525–530
   PubMed Web of Science ®Google Scholar
• . Lee EJ, Jameson JL. Gene therapy of pituitary diseases. J Endocrinol. 2005;185(3):353–362
   PubMed Web of Science ®Google Scholar